Hype against randomized trials for one topic, computed and dated 30 October 2026. It rates the topic, never a person, and gives no dosing and no sourcing.
The short version
229Kyearly wiki viewsEnglish Wikipedia, to 30 Sep 2026
73randomized-trial paperstyped on PubMed
3,142views per trial paperlower is better backed
Hype is nudging aheadthe verdictby the published rule
Finasteride
Hype is nudging ahead
3,142yearly views per trial paper
hype229K views a yearproof73 trial papers
Trials exist, but attention is running a step ahead of the record.
English Wikipedia readers opened the Finasteride article about 229K times in the year to 30 September 2026. PubMed holds 73 papers typed as randomized trials for it, which is 3,142 yearly views per trial paper. By the published rule that earns the verdict Hype is nudging ahead.
That is a statement about the gap between attention and trial record. It does not say whether Finasteride works or whether it is safe for anyone.
Finasteride is a prescription medicine and is listed here for education only.
How does it compare with the others?
Finasteride next to the other fourhype above, proof below, read 30 October 2026
Top chart: attention. Bottom chart: randomized-trial papers typed on PubMed. The highlighted bar is Finasteride. A big top bar over a small bottom bar is what the meter reads as hype ahead of the trials.